Purpose of review Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) bacteria represents a global emerging problem. Delayed prescription of an adequate treatment for VAP has been associated with higher morbidity and mortality. New molecules have been developed to face the need of compounds that are active against resistant Gram-positive and Gram-negative pathogens. The aim of this review is to summarize the current scenario of new therapeutic options for the treatment of VAP.
INTRODUCTION
Ventilator-associated pneumonia (VAP) represents one of the most common infections among critically ill patients, accounting for more than 50% of the antibiotic use in the ICU [1] . VAP is associated with high morbidity and mortality rates between 20 and 60%. Significant increases in length of stay and overall healthcare costs for VAP, estimated to be up to US 40 000 dollars per episode in adults, are also reported [2] . Despite the implementation of care bundles, the incidence of VAP has not changed significantly over the last decades, showing a persistent annual rate of 10% in mechanically ventilated patients [3] .
Antibiotic resistance has exponentially increased over the last decade, and the isolation of a multidrugresistant (MDR) pathogen has been identified as an independent predictor of initial inadequate antibiotic therapy and increased mortality [4] . In many ICUs, pathogens with limited therapeutic options such as methicillin-resistant Staphylococcus aureus (MRSA), MDR Pseudomonas aeruginosa, extendedspectrum beta-lactamase (ESBL) producing Enterobacteriacae, carbapenem resistant Enterobacteriaceae (CRE) and MDR A. baumannii are commonly isolated [5] .
The treatment of VAP has been limited for many years to vancomycin or linezolid for MRSA and to the use of antipseudomonal b-lactams or carbapenems (with or without an aminoglycoside or a fluoroquinolone) for Gram-negative pathogens [6] .
Triggered by an increasing prevalence of MDR isolates [7] , the past decade has seen a mayor expansion in antibiotic drug research [8] . All these efforts resulted in the development of novel new antibacterial compounds that are currently at various stages of clinical research. This review summarizes the current evidence on efficacy, microbiological spectrum and safety of antimicrobials that have completed phase II or III clinical trials or have been recently licensed for treatment of hospital-acquired pneumonia (HAP) and VAP.
NEW OXAZOLIDINONES: TEDIZOLID
Tedizolid is a new oxazolidinone approved by Food and Drugs Administration (FDA) and by the European Medical Agency (EMA) for the treatment of acute bacterial skin and soft tissue infections. Tedizolid demonstrated potent in-vitro activity against MRSA and vancomycin-resistant enterococci, including some linezolid-resistant strains [9] ( Tables 1 and 2 ).
Tedizolid presents multiple advantages over linezolid, including lower risk of gastrointestinal side effects, myelotoxicity, and lower risk of drugdrug interactions with compounds with serotonergic and adrenergic activity due to a weak and reversible in-vitro inhibition of the monoamine oxidase pathway. Due to a prolonged half-life of more than 10 h, tedizolid only needs to be administered once daily. Tedizolid high oral bioavailability (>90%) allows for an easy conversion from intravenous to oral formulation [9] .
Data from the pneumonia murine infection model and pharmacokinetic/pharmacodinamic (PK/PD) studies supported exploring its use in respiratory infections [10] . A study in adult volunteers demonstrated that tedizolid had high penetration into the epithelial lung fluid (ELF) and alveolar macrophages reaching levels approximately 40-fold and 20-fold, respectively, higher than free-drug exposures in plasma [11 & ].
KEY POINTS
The progressive increase of VAP caused by MDR organism is a major concern and is recognized as a cause of inadequate initial antibiotic therapy and increased mortality.
New antibiotics with activity against pathogens commonly implicated in VAP have recently become available and others are under investigation.
New antibiotics with activity against methicillin-resistant S. aureus such as tedizolid, plazomicin and eravacycline represent promising options for the treatment of VAP in patients with risk factors for MDR Gram-positive bacteria.
New antimicrobials with broad-spectrum activity against MDR Gram-negative bacteria can enhance the available armamentarium for VAP, although a limited number of compounds have shown activity against MDR Acinetobacter baumannii.
The availability of oral formulations of antimicrobials (e.g., tedizolid and eravacycline) may allow for early switch from intravenous to oral formulation in patients with VAP caused by MDR pathogens.
New nebulized antibiotics are a promising new option for VAP, although further evidence is required. A phase III, randomized, double blind study is currently ongoing comparing tedizolid (200-mg intravenous once daily for 7 days) versus linezolid (600-mg intravenous every 12 h for 10 days) for the treatment of ventilated patients with presumed Gram-positive HAP or VAP (ClinicalTrials.gov Identifier NCT02019420).
In our opinion, tedizolid could have a potential role for the treatment of VAP caused by MDR Grampositive bacteria (especially MRSA), with advantages such as high lung penetration, favorable safety profile, lower risk for drug-drug interactions, and availability of a once-daily formulation.
NEW CEPHALOSPORINS: CEFIDEROCOL
Cefiderocol, formerly S-649266, is a parenteral siderophore cephalosporin with a unique mechanism of bacterial cell entry. Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters and by passive diffusion through porin channels into the periplasmatic space [12] . Cefiderocol demonstrated in-vitro activity against ESBLproducing Enterobacteriacae and CRE (including classes A, B, and D), as well as against meropenem resistant P. aeruginosa, Stenotrophomonas maltophilia, and A. baumannii [12] (Tables 1-3) . Cefiderocol is currently in phase III of clinical development. The APEKS-cUTI study showed that cefiderocol met noninferiority results versus high dose of imipenem/cilastatin in hospitalized adult patients with complicated urinary tract infections (cUTIs) at risk for MDR Gram-negative bacteria and was well tolerated [13] .
Two phase III clinical trials are currently ongoing for various infections, including VAP ( Table 2 ). The APEKS-NP trial is a clinical study on nosocomial pneumonia. The aim of the trial is to compare all-cause mortality in participants receiving cefiderocol versus meropenem (both in association with linezolid), in adults with HAP, VAP and healthcare-associated pneumonia (HCAP) caused by Gram-negative pathogens (ClinicalTrials.gov Identifier: NCT03032380). In addition, a phase III trial (CREDIBLE-CR) has been initiated in 2017 to provide the evidence of efficacy of cefiderocol in patients with serious infections (HCAP, HAP, VAP, cUTI, and bloodstream infections, BSI) caused by carbapenem-resistant Gram-negative bacteria. In this trial, cefiderocol is compared with best available therapy including up to three antibacterial agents for carbapenem-resistant Gram-negative bacteria with either a polymyxin-based or nonpolymyxin-based regimen (ClinicalTrials.gov Identifier: NCT02714595).
Although waiting for definitive results from phase III trials, we believe that cefiderocol is a promising cephalosporin with an important potential for the treatment of VAP, thanks to the very broad spectrum of activity against carbapenem-resistant Gram-negative bacteria, including CRE, MDR P. aeruginosa, and MDR A. baumannii.
NEW CEPHALOSPORIN AND BETA-LACTAMASE INHIBITOR COMBINATIONS: CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM

Ceftolozane-tazobactam
Ceftolozane-tazobactam results from the association between a novel cephalosporin (ceftolozane) with a well established beta-lactamase inhibitor (tazobactam), which inhibits most class A and some class C beta-lactamases (Tables 1-3) .
Against P. aeruginosa, ceftolozane-tazobactam has been shown to overcome the most prevalent resistance mechanisms [e.g., chromosomal Ambler class C (AmpC), loss of outer membrane porin, and upregulation of efflux pumps] and demonstrated activity against carbapenem-resistant strains that do not produce carbapenemases, with low propensity for selection of resistances [14] . In both the United States and Western Europe, ceftolozane/tazobactam has proven to have a potent in-vitro activity against other Gram-negative bacteria, including ESBL-producing Enterobacteriacae, whereas Gram-negative pathogens harboring Klebsiella pneumoniae carbapenemase (KPC) or metallo-b-lactamases (MBLs) carbapenemases remain resistant [15] (Tables 1 and 3) . Ceftolozane-tazobactam is currently approved by FDA and EMA for treatment of complicated intraabdominal infections (cIAI) and cUTI at on label dosage (1.5 g every 8 h intravenous).
A study in healthy volunteers demonstrated that ceftolozane-tazobactam displayed a good ELF penetration after parenteral administration, implying a potential role for the treatment of respiratory infections [16] . However, PK/PD studies suggested that an increased dosage (3 g every 8 h intravenous) might be necessary for the treatment of pneumonia [17] . A phase III trial (ASPECT-NP) to assess the safety and efficacy of ceftolozane/tazobactam (3 g every 8 h intravenous) compared with meropenem (1 g every 8 h intravenous) for the treatment of VAP or ventilated HAP caused by P. aeruginosa is currently ongoing and is expected to be completed in 2018 (ClinicalTrials.gov Identifier NCT02070757).
Recently, a retrospective study including 21 patients treated with ceftolozane/tazobactam for MDR-P aeruginosa infections has been published. Most infections (18 out of 21) involved the respiratory tract (16 pneumonia, two tracheobronchitis), and ceftolozane-tazobactam was successful in 71% of patients. However, in-vivo resistance emerged in three patients (14%) [17, 18] .
We believe that ceftolozane-tazobactam represents an attractive option as a backbone for the treatment of MDR P. aeruginosa as well as a carbapenem-sparing regimen for the treatment of VAP.
Ceftazidime-avibactam
Ceftazidime-avibactam is a novel agent containing the third-generation cephalosporin ceftazidime and avibactam, a newly developed beta-lactamase inhibitor. Through a reversible and covalent mechanism, avibactam inactivates a wide range of bacterial betalactamases, including Ambler class A (ESBL and KPC), AmpC, and some class D serine beta-lactamases [e.g., oxacillinase (OXA) 48] [19] . In-vitro studies showed that the combination of ceftazidime-avibactam is highly effective against betalactamase-producing, cephalosporin-resistant isolates, namely Enterobacteriaceae and P. aeruginosa [20] . Avibactam has a limited activity against A. baumannii and other anaerobic Gram-negative rods and presents no activity against metallo-b-lactamases or Acinetobacter OXA carbapenemases [21] ( Tables 1-3) .
Resistance to ceftazidime-avibactam has been linked to specific de-novo mutations in the blaKPC-3 gene or to the production of multiple carbapenemases, reduced porin expression, and overexpression of efflux pumps [22] . Although the development of resistance has been described in patients who have received a relative short course of therapy, the relevance of this effect in clinical practice is unclear and needs further assessment [23 && ]. Ceftazidime-avibactam has been approved by FDA and EMA for the treatment of cUTIs, cIAIs, HAP/VAP, and for the treatment of infections due to aerobic Gram-negative organisms in adult patients when other treatments might not work [19, 24] .
Ceftazidime-avibactam displays an attractive bactericidal broad-spectrum activity and a linear pharmacokinetics with high lung penetration that supported exploring its use for respiratory infections [25 && ]. Results from a prospective study have been published, comparing ceftazidime-avibactam and meropenem for the treatment of nosocomial pneumonia, including VAP (REPROVE study, ClinicalTrials.gov Identifier NCT01808092) [26] . K. pneumoniae and P. aeruginosa were the predominant Gram-negative pathogens isolated at baseline, and 28.2% of the patients had at least one ceftazidime nonsusceptible isolates. Successful outcome was documented in 245/356 (68.8%) patients who received ceftazidime-avibactam compared with 270/370 (72.9%) patients who received meropenem, confirming the noninferiority of ceftazidimeavibactam for the treatment of nosocomial pneumonia caused by ceftazidime-nonsusceptible or ceftazidime-susceptible Gram-negative pathogens. In addition, success rates were similar in the cohort of patients with VAP. Overall, ceftazidime-avibactam was well tolerated in phase II and phase III trials, analyzing its efficacy in treatment of cUTI and cIAI. No differences in adverse event or serious adverse event rates were observed between ceftazidimeavibactam and comparator drugs in all published studies [27, 28] .
Although ceftazidime-avibactam has been used for treatment of several CRE infections with overall success rates ranging between 45 and 76% [23 && ], no randomized trials have specifically addressed its role for the treatment of CRE to date.
Ceftazidime-avibactam currently represents one of the drugs of choice for the treatment of CRE infections, In our opinion, ceftazidime-avibactam can be used in association with a second drug like gentamycin, fosfomycin, colistin (or, in the future, with plazomycin) and may have a role as a potential alternative to carbapenems in patients with nosocomial pneumonia (including VAP), or for empirical therapy in settings with high rates (>20-25%) of infections caused by ESBL-producing or CRE-producing Gram-negative bacteria.
Meropenem-vaborbactam is a combination agent containing an existing beta-lactam antibiotic (meropenem) with the cyclic boronate nonbeta-lactam beta-lactamase inhibitor (vaborbactam). Vaborbactam, a potent inhibitor of many beta-lactamases, protects meropenem from the hydrolysis of different Gram-negative organisms producing class A and class C serine beta-lactamases, including KPC [29] . Vaborbactam has no antibacterial activity and is structurally distinct from other new beta-lactamase inhibitors such as avibactam or relebactam [30] . The addition of vaborbactam to meropenem reduces by more than 16-fold the minimum inhibitory concentration (MIC) of meropenem for different Enterobacteriaceae. However, vaborbactam had little to no effect on meropenem-nonsusceptible A. baumannii containing OXA-type carbapenemases or for P. aeruginosa [31] (Tables 1 and 2) .
Meropenem -vaborbactam has been recently approved by the US FDA for the treatment of cUTI, including pyelonephritis (TANGO I). Meropenem -vaborbactam was compared with the best available therapy in a multinational, open-label randomized trial concerning treatment of different infections caused by CRE including UTI, BSI, and HAP/VAP (TANGO II) [32] . End of treatment results showed that 57.1% of patients treated with meropenem -vaborbactam and 33.3% of those treated with the best available therapy were cured (P ¼ 0.04). In the cohort of patients with HAP/VAP and bacteremia, treatment with meropenem -vaborbactam was associated with a lower day-28 all-cause mortality rate compared with comparators (25.0 versus 44.4%, respectively). Moreover, the administration of meropenem -vaborbactam was associated, across all groups, with decreased nephrotoxicity and fewer treatment-related adverse events.
Meropenem-vaborbactam is currently compared with piperacillin/tazobactam in a randomized, double blind multinational trial involving adult patients with HAP/VAP (TANGO III) (ClinicalTrials.gov Identifier: NCT03006679) ( Table 2 ).
In conclusion, meropenem-vaborbactam could be an attractive option for the treatment of CRE VAP, especially in consideration of its lower mortality rates, as recently documented. Further studies, however, are needed to understand meropenemvaborbactam's potential role in the antimicrobial armamentarium.
Imipenem-relebactam
Imipenem-relebactam is a combination agent containing an existing beta-lactam antibiotic (imipenem-cilastatin) with the nonbeta-lactam betalactamase inhibitor (relebactam). Similarly to avibactam, relebactam inhibits the activity of class A and C beta-lactamase, but does not have activity against metallo-beta-lactamase. Furthermore, relebactam has no activity against class D carbapenemases [33] (Table 3) .
The combination of imipenem-cilastatin with relebactam has shown to have synergistic activity against a wide spectrum of MDR Gram-negative pathogens including P. aeruginosa and KPC-producing K. pneumoniae and Enterobacter spp. In-vitro studies have shown that combination of relebactam with imipenem results in a 64-fold reduction in imipenem MIC values for KPC-producing K. pneumoniae and in eight-fold decrease for imipenemresistant P. aeruginosa [33] (Tables 1 and 2 ).
Two phase II clinical studies have been performed including patients with cIAI or with cUTI. In those studies, combination of Imipenem (500 mg every 6 h) with relebactam at different dosage (125 and 250 mg) were compared with imipenem-cilastatin alone, showing high clinical response (>96%) in both infections and for both dosages [34, 35] .
Relebactam and imipenem have been demonstrated to display a good intrapulmonary penetration (ELF 53% of plasma), fostering the development of clinical studies on nosocomial respiratory infections [36] . A phase III, randomized, double-blind, controlled trial of imipenem-relebactam versus colistimethate sodium þ imipenem/cilastatin in patients with infections (including HAP and VAP) due to imipenem-resistant strains has been completed, but results are not yet available (ClinicalTrials.gov Identifier: NCT02452047). Another phase III study is currently ongoing to assess the noninferiority to piperacillin/tazobactam in patients with HAP or VAP (ClinicalTrials.gov Identifier: NCT02493764) Imipenem-relebactam could offer an important new treatment option as part of an empirical or targeted therapy for VAP due to MDR Gram-negative bacteria.
NEW AMINOGLYCOSIDES: PLAZOMICIN
Plazomicin is a next-generation, semisynthetic aminoglycoside which acts by inhibiting bacterial protein synthesis and exhibits dose-dependent bactericidal activity. Plazomicin has shown potent activity against Gram-positive bacteria such as MRSA, including aminoglycoside-resistant isolates [37] . Plazomycin was modified to resist aminoglycoside-modifying enzymes that are often present in CRE. Against Gram-negative bacteria, plazomicin is active toward MDR Enterobacteriaceae, including CRE and isolates resistant to currently available aminoglycosides (Table 2) . Compared with its efficiency against Enterobacteriaceae, plazomicin is less active against nonfermenting Gram-negative bacteria. Against MDR P. aeruginosa plazomicin MICs were similar to MICs of other aminoglycosides. Significantly improved activity has been observed in OXA-producing A. baumannii compared with other aminoglycosides [38] ( Table 1) .
The PK/PD properties of plazomicin revealed a linear and dose-proportional profile, making plazomicin a promising candidate for the treatment of nosocomial pneumonia [39] . The phase III CARE study (ClinicalTrials.gov Identifier NCT01970371) evaluated the efficacy and safety of plazomicin versus colistin as part of a definitive combination regimen for the treatment of serious infections due to CRE and has been recently completed. Each drug was combined with a second antibiotic, either meropenem or tigecycline. The CARE trial enrolled 29 BSI and eight patients with HAP/VAP. A lower rate of mortality or serious disease-related complications was observed for plazomicin compared with colistin (23.5 versus 50.0%, respectively; 90% confidence interval: À0.7, 51.2%) [40] . In addition, plazomicin showed a favorable safety profile and was associated with a lower incidence of drug-related adverse events, including serum creatinine elevations. There were no events associated with potential ototoxicity and no study drug-related deaths in either cohort [40] .
Plazomicin is characterized by a wide spectrum of activity including MRSA and MDR Gram-negatives and could offer an important new treatment option as part of a combination regimen for patients with VAP.
OTHER POTENTIAL NEW ANTIBIOTICS FOR VENTILATOR-ASSOCIATED PNEUMONIA
Several drugs for the treatment of hospital-acquired infections are currently being investigated in clinical trials with therapeutic potential for lung infections, including VAP.
MONOBACTAM AND NOVEL BETA-LACTAMASE INHIBITOR: AZTREONAM-AVIBACTAM
Aztreonam, a monobactam antibiotic, is active against MBL-producing bacteria, but it is hydrolyzed by Ambler class A beta-lactamases (e.g., ESBL and KPCs) and class C (e.g., AmpC) beta-lactamases. Since many MBL-producing Gram-negative bacteria may simultaneously express beta-lactamases or carbapenemases that could hydrolyze aztreonam, the combination with avibactam is able to inhibit cell wall synthesis in MBL-producing strains despite the presence of other cocarried beta-lactamases [41] . Aztreonam-avibactam showed a potent in-vitro activity against ESBL, class C b-lactamase, MBL, and KPC-producing strains with an activity 10 times that of aztreonam alone (Tables 1 and 3 ). However, limited activity has been shown against A. baumannii or P. aeruginosa compared with aztreonam alone [41] . A phase III clinical trial to compare aztreonamavibactam (with or without metronidazole) with meropenem (with or without colistin) for the treatment of HAP, VAP, and cIAI due to Gram-negative bacteria for which there are limited or no treatment options will be performed starting in March 2018.
Aztreonam-avibactam may represent an interesting alternative for VAP caused by MBL-producing strains.
Cephalosporin R b-lactamase inhibitor: ceftaroline-avibactam
Ceftaroline is a new fifth-generation cephalosporin characterized by a unique activity against MRSA and Gram negatives (with the exception of ESBL and CRE) and has been approved for communityacquired pneumonia (Table 1) . Previous data support further evaluation of ceftaroline fosamil as an effective treatment option for HAP and VAP [42] . Results from clinical trials are pending, and no studies have been performed for the use of ceftaroline/avibactam for nosocomial pneumonia, although this drug showed promising in-vitro activity against pathogens that may be involved in VAP.
NEW TETRACYCLINES: ERAVACYCLINE
Eravacycline is a promising investigational, intravenous, and oral synthetic fluorocycline that is structurally similar to tigecycline [43] . Like other tetracyclines, eravacycline inhibits bacterial protein synthesis and demonstrated broad-spectrum antimicrobial activity against Gram-positive, Gram-negative, and anaerobic bacteria with the exception of P. aeruginosa, showing more potent activity compared with tigecycline (Table 1) . Several studies in animal models, including mouse lung infection, demonstrated the in-vivo efficacy of eravacycline [43] . Phase III clinical trials in cIAI and cUTI have been completed [44] . A phase I study in healthy adults demonstrated that eravacycline penetrated into ELF and alveolar macrophages reaching levels approximately six-fold and 50-fold, respectively, higher than free-drug exposures in plasma, supporting further study of eravacycline for patients with respiratory infections [45] .
Eravacycline may offer an alternative option for patients with VAP caused by MDR Gram-negative bacteria, including MDR Acinetobacter. In addition, its high oral bioavailability (>90%) allows for the switch from an intravenous to an oral formulation.
OUTER MEMBRANE PROTEIN TARGETING ANTIBIOTIC: MUREPAVADIN
Murepavadin (POL7080) is a 14-amino-acid cyclic peptide and belongs to a novel class of outer membrane protein targeting antibiotic with highly specific activity against P. aeruginosa, including MDR strains. Murepravadin targets the lipopolysaccharide transport portin D, an outer membrane protein of P. aeruginosa, which is critical for lipopolysaccharide biogenesis (Table 1) . This drug has shown to be highly effective in several animal infection models with ELF concentration comparable with free plasma concentration [46] . Given its specific mechanism of action, murepavadin is highly effective and unlikely to generate resistance or negatively affect the patient's native bacterial flora. Nephrotoxicity, however, remains a concern associated with the use of murepavadin and requires further investigation. A phase II clinical trial has been completed (ClinicalTrials.gov Identifier: NCT02096328) to assess pharmacokinetics, safety and efficacy of murepavadin coadministered with the standard of care in patients with VAP due to suspected or documented P. aeruginosa infection showing promising results [47 && ]. In conclusion, muprepavadin could represent a promising option to be combined with standard of care.
NEBULIZED ANTIBIOTICS
Perhaps the key advantage of administering antibiotics by inhalation rather than via intravenous infusion is the potential to deliver high concentrations of antibiotic directly to the site of lung infection [48, 49] with low systemic absorption, leading to decreased adverse effects and superinfections [5] . These concentrations may also exceed the MICs for MDR pathogens. Aerosolized antibiotics have been largely used off-label for the treatment of pneumonia in mechanically ventilated patients, but there is still no consensus for such treatment. New inhaled antibiotic options are currently under development for the treatment of VAP.
A specially formulated amikacin inhalation solution (BAY41-6551, Amikacin Inhale) is an investigational drug-device combination consisting of a specially formulated amikacin for inhalation administered by the pulmonary drug delivery system that is a new vibrating mesh nebulizer. Previous phase II studies showed that BAY41-6551 always exceeded the amikacin MIC for Gram-negative microorganisms [50] and was safe and well tolerated for the treatment of VAP [51] . A global phase III clinical study (INHALE) program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia did not demonstrate superiority versus standard of care and aerosolized placebo (ClinicalTrials.gov Identifier: NCT01004445).
A phase I clinical trial evaluated the pharmacokinetics and safety/tolerability of amikacin-fosfomycin inhalation system (AFIS) in mechanically ventilated patients with VAP. High tracheal aspirate concentrations of amikacin and fosfomycin were achieved in patients with VAP, and no adverse respiratory effects were noted during or following drug administration [52 && ]. Data from a placebocontrolled phase II study for the treatment of VAP caused by Gram-negative bacteria encompassing 143 patients have been published. In this trial, adjunctive aerosol therapy (300-mg amikacin/ 120-mg fosfomycin twice daily) was compared with standard of care intravenous antibiotics to assess the safety and efficacy of AFIS. The results showed that AFIS was ineffective in improving clinical outcomes despite reducing bacterial burden [52 && ]. Other inhaled antibiotics with potential use in VAP include inhaled ciprofloxacin, arbekacin, murepavadin, and BAL30072 [53,54 & ]. In conclusion, nebulizer technology continues to evolve. Improvements in nebulizer capabilities may offer new treatment options that maximize the potential benefits of inhaled antibiotic therapy. Recent advances are promising to deliver nebulized therapy options with optimal particle sizes and to achieve improved drug delivery throughout the lung, while maintaining low systemic exposures. The combination of specifically designed drug formulations and modern, high efficiency delivery devices has the potential to overcome current challenges in the aerosolized treatment of pneumonia. Increasing resistance and limited efficacy of currently available intravenous antibiotics for the treatment of pneumonia in intubated and mechanically ventilated patients are a growing cause for concern, and the choice of effective treatments is limited.
CONCLUSION
VAP management requires prompt and adequate antibiotic administration and exposure. The progressive increase of nosocomial respiratory tract infections caused by MDR organisms have been associated with delays in the prescription of an adequate antibiotic treatment and increased mortality, representing a major concern. New approved and investigational agents for the treatment of respiratory tract infections represent promising options to preserve and enhance our antibiotic armamentarium. The most attractive characteristic of new drugs is the broad-spectrum activity against MDR organisms, particularly Gram negatives, which still represent a major challenge in clinical practice because of the lack of new therapeutic options. However, studies assessing the efficacy of these agents in real-life are needed, particularly regarding the potential opportunity for a monotherapy in patients with infections sustained by MDR Gramnegative pathogens. The cost-efficacy of new agents with anti-MRSA activity needs to be evaluated and compared with older agents, to optimize the use of healthcare resources and patients' outcomes. Positioning and differentiation of new treatment options, along with the optimization of available therapeutic options are needed to incorporate these drugs in daily clinical use to face the challenge of antimicrobial resistance in patients with VAP.
